ICANS

Clinical trials for ICANS explained in plain language.

Never miss a new study

Get alerted when new ICANS trials appear

Sign up with your email to follow new studies for ICANS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1 Completed 1

Can a blue dye tame Immunotherapy's dangerous side effects?

Disease control Recruiting now

This early-phase trial tests whether methylene blue, a dye used in medicine for other conditions, can safely treat two serious side effects of certain cancer immunotherapies: cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS). The study will enroll 18 adults…

Matched conditions: ICANS

Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control

Last updated Jun 26, 2026 16:24 UTC

ICANS

Get alerted when new ICANS trials appear

Can a blue dye tame Immunotherapy's dangerous side effects?